<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106053</url>
  </required_header>
  <id_info>
    <org_study_id>NEDA-Pramipexole</org_study_id>
    <nct_id>NCT01106053</nct_id>
  </id_info>
  <brief_title>Pramipexole for Binge Eating Disorder</brief_title>
  <official_title>An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuropsychiatric Research Institute, Fargo, North Dakota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuropsychiatric Research Institute, Fargo, North Dakota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects that the drug pramipexole has on mood,&#xD;
      food craving, and other behaviors that may be related to binge eating disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants were recruited and study has been closed.&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of binge eating</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and extent of craving for food using validated instruments</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of mood ratings using a validated instrument</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label trial of pramipexole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).</description>
    <arm_group_label>Pramipexole</arm_group_label>
    <other_name>Mirapex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18-50 years&#xD;
&#xD;
          -  Women of child-bearing potential and males must agree to practice an accepted method&#xD;
             of birth control. All women must have a negative pregnancy test at baseline.&#xD;
&#xD;
          -  Good general health as demonstrated by history and physical examination.&#xD;
&#xD;
          -  Body mass index of 30 kg/m2 or higher at the screening visit.&#xD;
&#xD;
          -  Meet criteria for binge eating disorder as assessed through the SCID-1 and EDE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any unstable medical condition, or any current or past medical condition&#xD;
             which in the opinion of the study physician and/or the principal investigator may&#xD;
             increase the risks associated with pramipexole and study participation. Medical&#xD;
             appropriateness will be determined through history and physical exam.&#xD;
&#xD;
          -  Subjects with any current Axis I psychiatric diagnosis as determined through the&#xD;
             Structured Clinical Interview for DSM-IV for Axis I disorders (SCID-1) interview&#xD;
             (aside from BED).&#xD;
&#xD;
          -  Subjects with a Hamilton Depression Rating Scale score greater than or equal to 12 at&#xD;
             the screening visit.&#xD;
&#xD;
          -  Subjects who report any history of hallucinations or delusions.&#xD;
&#xD;
          -  Participants taking an antidepressant or other regularly used psychotropic medication&#xD;
             which may confound the study results&#xD;
&#xD;
          -  Subjects with any current or history of an impulse control spectrum disorder, other&#xD;
             than binge eating disorder,(such as pathological gambling, compulsive shopping, etc.)&#xD;
             at screening as determined by the Structured Clinical Interview for DSM-IV Impulse&#xD;
             Control Module.&#xD;
&#xD;
          -  Subjects with any history of suicide attempts or current suicidal ideations.&#xD;
&#xD;
          -  Subjects that have used tobacco products on a routine basis within the past six&#xD;
             months.&#xD;
&#xD;
          -  Subjects enrolled in any formal treatment programs or research protocols for binge&#xD;
             eating disorder at present, or within the past 30 days.&#xD;
&#xD;
          -  Subjects routinely taking any medication known to produce weight change (ex.&#xD;
             olanzapine, amitriptyline, steroid medications, etc., other than oral contraceptives,&#xD;
             stable thyroid replacement drugs, etc.), or medications with drug-drug interactions&#xD;
             with pramipexole.&#xD;
&#xD;
          -  Subjects who are currently breast-feeding.&#xD;
&#xD;
          -  Subjects who have participated in an investigational drug trial in the past 30 days.&#xD;
&#xD;
          -  Subjects who meet DSM IV-TR criteria for alcohol or drug abuse in the past year.&#xD;
&#xD;
          -  Subjects with an allergy to pramipexole or tablet constituents.&#xD;
&#xD;
          -  Subjects with hepatic dysfunction as determined through a hepatic panel obtained at&#xD;
             the screening visit.&#xD;
&#xD;
          -  Subjects with an elevated blood pressure or pulse at screening (140/90 mmHg or above&#xD;
             or pulse of greater than 100 beats/minute after being seated and stationary for at&#xD;
             least five minutes, or as determined at the discretion of the study physician and/or&#xD;
             principal investigator) or history of serious cardiac events (myocardial infarction,&#xD;
             arrhythmia, stroke, etc).&#xD;
&#xD;
          -  Subjects with a history of renal dysfunction or with a creatinine clearance of less&#xD;
             than 60 ml/min based upon a serum creatinine obtained during screening and as&#xD;
             calculated with the Cockroft and Gault equation.&#xD;
&#xD;
          -  Subjects with a positive urine drug screen.&#xD;
&#xD;
          -  Any participant with Parkinson's disease or symptoms suggestive of probable&#xD;
             Parkinson's disease.&#xD;
&#xD;
          -  Subjects who have an Epworth Sleep Scale (ESS) score of &gt;7 at screening. ESS scores &gt;&#xD;
             7 have been associated with an increased risk of sleep attacks (Plowman et al., 2005).&#xD;
&#xD;
          -  Any participant who demonstrates clinically significant orthostatic blood pressure&#xD;
             changes or is symptomatic during the screening visit, as defined under &quot;orthostatic&#xD;
             blood pressure monitoring.&quot;&#xD;
&#xD;
          -  History of bariatric surgery.&#xD;
&#xD;
          -  Participants who report a history of obstructive sleep apnea, excessive fatigue, or&#xD;
             any sleep disorder which in the opinion of the principal investigator or study medical&#xD;
             personnel would increase the participant's risk of experiencing excessive somnolence&#xD;
             with pramipexole.&#xD;
&#xD;
          -  Participant has had a change in medication regimen in the last month (dose, starting a&#xD;
             new medication, or stopping a medication).&#xD;
&#xD;
          -  Participant is employed by, or has an immediate family member employed by NRI.&#xD;
&#xD;
          -  Participant has participated in a formal weight loss program in the last month (e.g.&#xD;
             Weight Watchers, Jenny Craig, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine J Steffen, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuropsychiatric Research Institute, Fargo, ND</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.nrifargo.com</url>
    <description>NRI website</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuropsychiatric Research Institute, Fargo, North Dakota</investigator_affiliation>
    <investigator_full_name>Kristine Steffen</investigator_full_name>
    <investigator_title>Reseach Scientist</investigator_title>
  </responsible_party>
  <keyword>Binge eating disorder</keyword>
  <keyword>Food craving</keyword>
  <keyword>Obesity</keyword>
  <keyword>Pramipexole</keyword>
  <keyword>Mirapex</keyword>
  <keyword>Binge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

